The Power of Innovation Centres in US Healthcare

By Staff Writer

November 4, 2023

Unveiling the Potential of Healthcare Innovation Centres


A growing trend in US healthcare systems, innovation centres are creating waves in the sector. These centres, which prioritise the quick creation, operationalisation, and assessment of novel innovations—many of which are digital—are transforming the healthcare industry. They are usually developed in response to issues that healthcare systems encounter, with a shared emphasis on problem-solving and real-time healthcare delivery.

These centres focus on three main areas: rapidly testing, assessing, and scaling domestic initiatives; disseminating creative, effective ideas throughout the healthcare system; and creating new solutions and ideas from data, experiences, and activities. Innovation centres can provide excellent, hyperlocal research and quality improvement when they are operating at peak efficiency.



The Success and Sustainability of Innovation Centres


However, it’s estimated that up to 90% of industry innovation centres fail. Despite this, healthcare innovation centres have seen significant growth in the past decade. The key to their success and sustainability lies in how they define their value and success.


Innovation centres often focus on demonstrating value in a creative way, rather than commercialisation of innovations. They add value to their institutions through their projects and innovations. For instance, they may create a decision support tool in the electronic health record to identify patients who smoke upon hospital admission. This not only benefits the patients but also the institution by meeting quality metrics.

These centres also offer value by “failing fast”, spending less money to understand whether a project or innovation will or will not work. This sets them apart from the wider healthcare organisation, which tends to be slower and more cautious.

Centres for healthcare innovation can become sustainable entities within US healthcare institutions. However, they must work effectively with their institutions to define success more broadly than purely financial return on investment. The field needs to develop more robust means of measuring these nonfinancial benefits for long-term success.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.